CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 8, 2006--Curis, Inc. (NASDAQ: CRIS - News), a therapeutic drug development company, today announced the initiation of a new strategic focus on seeking to develop later-stage drug development programs and to de-emphasize its earlier-stage discovery research. This new direction represents an expansion of Curis' continuing strategy to mitigate risk by seeking to both create and acquire a broad portfolio of later-developmental stage assets and maximize the Company's capacity and competencies in drug development. In addition to furthering our internal development candidates, Curis will continue to evaluate in-licensing opportunities to augment the Company's proprietary later stage preclinical pipeline.
